Modality
mRNA
MOA
Anti-Aβ
Target
C5
Pathway
Notch
SLE
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
Dec 2019
→ Dec 2025
Phase 1Current
NCT08610300
468 pts·SLE
2019-12→2025-12·Terminated
468 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-134mo agoInterim· SLE
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1
Termina…
Catalysts
Interim
2025-12-13 · 4mo ago
SLE
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08610300 | Phase 1 | SLE | Terminated | 468 | DOR |
Competitors (10)